0 Items
Toll Free (US) - +1-866-598-1553
sales@precisionbusinessinsights.com
Antiretroviral Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

Antiretroviral Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00 – $ 8,900.00

Antiretroviral Drugs Market : By Drug Class (Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, Chemokine Receptor Inhibitors, Others), By Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and Geography

 

Request Sample Request Methodology
Request Sample Read More
$ PRICE - $ 3,000.00 – $ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00 – $ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,
Report

Description

Antiretroviral Drugs Market size was valued at USD 62.9 billion in 2021, growing at a CAGR of 3.6% during the forecast period 2022-28. Cytopathic effects in cells in the brain and infected T cells may develop immune deficiencies and neurological diseases induced by HIV and related lentiviruses. Retrovirus causes immunological diseases including HIV and T-Cell leukaemia. Acquired immune deficiency syndrome (AIDS) caused by retrovirus known as human immunodeficiency virus (HIV) and T-Cell leukaemia caused by human T lymphotropic virus (HTLV). Antiretroviral drugs are the drugs that acts or inhibit certain process in viral replication and inhibits further worsening of the diseases. Globally antiviral drugs market driven by increased cases of retroviral infections such as especially HIV/AIDS. According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS related illness in the same year. The higher prevalence of HIV owing to the various factors such as lack of availability of medication for the treatment of HIV infection, promising pipeline drugs, increased funding by the government are expected to bolster the antiretroviral drugs market over the forecast period. However, high costs of R&D and stringent regulatory procedures hampering the global Anti-retroviral Drugs Market. Furthermore, availability of the generic versions of blockbuster drugs affecting the market revenue of antiretroviral drugs. Antiretroviral drugs market is expected to grow at significant rates during forecasting period owing to pipeline drugs such as doravirine (Merck & Co.), fostemsavir (Bristol-Myers Squibb), rilpivirine (Tibotec) etc. Market players are adopting strategies like mergers and acquisitions to improve the market share. In December 2015, ViiV Healthcare purchased Bristol-Myers Squibb’s late stage HIV R&D assets. Market players are also actively collaborating with government and non-government organizations to educate the people and increase awareness related to retroviral diseases. For instance, in September 2016, in an effort to eradicate and combat HIV/AIDS and hypertension in Africa, under U.S. Presidents Emergency Plan for Aids Relief (PEPFAR), United States partnered with AstraZeneca Plc in donating US$10 million to HIV/AIDS funding. In November 2016, ViiV Healthcare (Pfizer and GlaxoSmithKline’s joint venture) received U.S. FDA approval to market selzentry for the treatment of CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents.

 

Antiretroviral Drugs Market

MARKET SUMMARY
-
3.6%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR–- 3.6%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Antiviral Drugs Market

  • Global antiretroviral drugs market is segmented based on drug class, route of administration, and distribution channel.
  • Retroviruses is a single stranded RNA containing virus with DNA intermediate. Retrovirus use enzyme, reverse transcriptase to copy their RNA into DNA of the host cell.
  • The retrovirus integrates its viral DNA into DNA of the host cell, which allows the retrovirus to replicate. Retroviruses can cause different outcomes for the infected cell.
  • Retroviruses are capable of inducing autoimmune, immunosuppressive, and neurological illnesses. Some retroviruses, such as the spumaviruses and lentiviruses are capable of directly killing cells.
Market Key Players
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.
Antiretroviral Drugs Market Dynamics

However, as viral illnesses such as HIV, Herpes, Influenza, and others become more common, demand for antiviral drugs is likely to rise over the forecast period. According to UNAIDS, more than 37 million people around the world would be living with HIV by 2020. In 2020, around 1.5 million more people will have contracted HIV. Overall, the COVID-19 pandemic has greatly improved market growth in 2020, however the pandemic has had a negative influence on other antiviral drug applications. Over the predicted period, a primary element driving demand for antiviral medications is the rising incidence of viral illness over the world. According to the WHO, an estimated 325 million individuals worldwide have hepatitis, with 71 million of these having chronic hepatitis C virus infection. Furthermore, the United States Department of Health and Human Services estimates that 2.4 million people in the country have hepatitis C, with roughly 850,000 people infected with hepatitis B. The global need for antiviral medications is expected to rise as the number of patients grows.

North-America Got Significant Share

Anti-retroviral Drugs Market

Geographically global antiretroviral drugs market is segmented into five key regions Viz. North America, Europe, Asia- Pacific, Latin America, and Middle East & Africa. North America antiretroviral market is driven by introduction of combination therapies such as antiretroviral therapy dosages by key players in the region. Asia Pacific antiretroviral drugs market expected to be fastest growing due to developing healthcare infrastructure and increase in government and non-government organization initiatives creating awareness of retroviral diseases especially HIV/AIDS. Asia Pacific region has many generic drug manufacturing companies that are already have significant presence in global retroviral drugs in market. Middle East and Africa region is expected to be key region owing to availability of large pool of patients with retroviral diseases. However, poor healthcare infrastructure and lack of awareness related to retroviral diseases among healthcare professionals expected to hamper market revenue growth in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015 to 2020) and forecast (2021 to 2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Antiretroviral Drugs Market Segmentation

segmentation-block-image

By drug class

    • Nucleoside Reverse Transcriptase Inhibitors (NRT’s)
    • Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)
    • Protease Inhibitors
    • Integrate Inhibitors
    • Fusion Inhibitors
    • Chemokine Receptor Inhibitors
    • Others
segmentation-block-image

administration

    • Oral
    • Parenteral
segmentation-block-image

distribution channel

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others
segmentation-block-image

Geography

    North America

    • US
    • Canada

    Europe

    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Russia
    • Poland
    • Rest of Europe

    Asia-Pacific

    • Japan
    • China
    • India
    • Australia & New Zealand
    • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
    • South Korea
    • Rest of Asia-Pacific

    Latin America

    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America

    Middle East and Africa (MEA)

    • Gulf Cooperation Council (GCC) Countries
    • Israel
    • South Africa
    • Rest of MEA
Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Report

Table Of Content

  1. Executive summary
  2. Global Antiretroviral Drugs Market Introduction

2.1. Global Antiretroviral Drugs Market – Taxonomy

2.2. Global Antiretroviral Drugs Market –Definitions

2.2.1. Drug Class

2.2.2. Route of Administration

2.2.3. Distribution Channel

  1. Global Antiretroviral Drugs Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Antiretroviral Drugs Market Dynamics – Factors Impact Analysis

3.6. Global Antiretroviral Drugs Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Antiretroviral Drugs Market – Product Innovations

  1. Global Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Oppurtunity Analysis

  1. Global Antiretroviral Drugs Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024

5.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3. Market Opportunity Analysis

5.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3. Market Opportunity Analysis

5.3. Protease Inhibitors

5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.3.3. Market Opportunity Analysis

5.4. Integrate Inhibitors

5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.4.3. Market Opportunity Analysis

5.5. Fusion Inhibitors

5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.5.3. Market Opportunity Analysis

5.6. Chemokine Receptor Inhibitors

5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.6.3. Market Opportunity Analysis

5.7. Others

5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.7.3. Market Opportunity Analysis

  1. Global Antiretroviral Drugs Market Forecast, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024

6.1. Parenteral

6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.1.3. Market Opportunity Analysis

6.2. Oral

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.3. Market Opportunity Analysis

  1. Global Antiretroviral Drugs Market Forecast, By Distribution Channel , 2013 – 2017 and Forecast, 2018 – 2024

7.1. Retail Pharmacies

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.1.3. Market Opportunity Analysis

7.2. Hospital Pharmacies

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.3.3. Market Opportunity Analysis

7.4. Others

7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.4.3. Market Opportunity Analysis

  1. Global Antiretroviral Drugs Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024

8.1. North America

8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.5.3. Market Opportunity Analysis

8.6. Global Antiretroviral Drugs Market – Opportunity Analysis Index, By Drug Class, Route of administration, Distribution Channel and Region, 2018 – 2024

  1. North America Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

9.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

9.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

9.1.3. Protease Inhibitors

9.1.4. Integrate Inhibitors

9.1.5. Fusion Inhibitors

9.1.6. Chemokine Receptor Inhibitors

9.1.7. Others

9.2. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Parenteral

9.2.2. Oral

9.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.3.1. Retail Pharmacies

9.3.2. Hospital Pharmacies

9.3.3. Online Pharmacies

9.3.4. Others

9.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Antiretroviral Drugs Market – Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 – 2024

9.6. North America Antiretroviral Drugs Market Dynamics – Trends

  1. Europe Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

10.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

10.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

10.1.3. Protease Inhibitors

10.1.4. Integrate Inhibitors

10.1.5. Fusion Inhibitors

10.1.6. Chemokine Receptor Inhibitors

10.1.7. Others

10.2. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Parenteral

10.2.2. Oral

10.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Retail Pharmacies

10.3.2. Hospital Pharmacies

10.3.3. Online Pharmacies

10.3.4. Others

10.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

10.5. Europe Antiretroviral Drugs Market – Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 – 2024

10.6. Europe Antiretroviral Drugs Market Dynamics – Trends

  1. Asia-Pacific Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

11.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

11.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

11.1.3. Protease Inhibitors

11.1.4. Integrate Inhibitors

11.1.5. Fusion Inhibitors

11.1.6. Chemokine Receptor Inhibitors

11.1.7. Others

11.2. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Parenteral

11.2.2. Oral

11.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Retail Pharmacies

11.3.2. Hospital Pharmacies

11.3.3. Online Pharmacies

11.3.4. Others

11.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Antiretroviral Drugs Market – Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 – 2024

11.6. Europe Antiretroviral Drugs Market Dynamics – Trends

  1. Latin America Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

12.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

12.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

12.1.3. Protease Inhibitors

12.1.4. Integrate Inhibitors

12.1.5. Fusion Inhibitors

12.1.6. Chemokine Receptor Inhibitors

12.1.7. Others

12.2. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Parenteral

12.2.2. Oral

12.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Retail Pharmacies

12.3.2. Hospital Pharmacies

12.3.3. Online Pharmacies

12.3.4. Others

12.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Antiretroviral Drugs Market – Opportunity Analysis Index, By  Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 – 2024

12.6. Latin America Antiretroviral Drugs Market Dynamics – Trends

  1. Middle East and Africa Antiretroviral Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

13.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT’s)

13.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s)

13.1.3. Protease Inhibitors

13.1.4. Integrate Inhibitors

13.1.5. Fusion Inhibitors

13.1.6. Chemokine Receptor Inhibitors

13.1.7. Others

13.2. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Parenteral

13.2.2. Oral

13.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Retail Pharmacies

13.3.2. Hospital Pharmacies

13.3.3. Online Pharmacies

13.3.4. Others

13.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.4.1. Brazil

13.4.2. Mexico

13.4.3. Argentina

13.4.4. Venezuela

13.4.5. Rest of Latin America

13.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.5.1. Gulf Cooperation Council (GCC) Countries

13.5.2. Israel

13.5.3. South Africa

13.5.4. Rest of MEA

13.6. MEA Antiretroviral Drugs Market – Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2018 – 2024

13.7. MEA Antiretroviral Drugs Market Dynamics – Trends

  1. Competition Landscape

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Abbott Laboratories (U.S.)

14.2.2. AstraZeneca plc (U.K.)

14.2.3. Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S)

14.2.4. Gilead Sciences (U.S.)

14.2.5. GlaxoSmithKline Plc (U.K.)

14.2.6. F. Hoffmann-La Roche AG (Switzerland)

  1. Research Methodology
  2. Key Assumptions and Acronyms
Report

Company Profile

  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.

Description

Antiretroviral Drugs Market size was valued at USD 62.9 billion in 2021, growing at a CAGR of 3.6% during the forecast period 2022-28. Cytopathic effects in cells in the brain and infected T cells may develop immune deficiencies and neurological diseases induced by HIV and related lentiviruses. Retrovirus causes immunological diseases including HIV and T-Cell leukaemia. Acquired immune deficiency syndrome (AIDS) caused by retrovirus known as human immunodeficiency virus (HIV) and T-Cell leukaemia caused by human T lymphotropic virus (HTLV). Antiretroviral drugs are the drugs that acts or inhibit certain process in viral replication and inhibits further worsening of the diseases. Globally antiviral drugs market driven by increased cases of retroviral infections such as especially HIV/AIDS. According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS related illness in the same year. The higher prevalence of HIV owing to the various factors such as lack of availability of medication for the treatment of HIV infection, promising pipeline drugs, increased funding by the government are expected to bolster the antiretroviral drugs market over the forecast period. However, high costs of R&D and stringent regulatory procedures hampering the global Anti-retroviral Drugs Market. Furthermore, availability of the generic versions of blockbuster drugs affecting the market revenue of antiretroviral drugs. Antiretroviral drugs market is expected to grow at significant rates during forecasting period owing to pipeline drugs such as doravirine (Merck & Co.), fostemsavir (Bristol-Myers Squibb), rilpivirine (Tibotec) etc. Market players are adopting strategies like mergers and acquisitions to improve the market share. In December 2015, ViiV Healthcare purchased Bristol-Myers Squibb’s late stage HIV R&D assets. Market players are also actively collaborating with government and non-government organizations to educate the people and increase awareness related to retroviral diseases. For instance, in September 2016, in an effort to eradicate and combat HIV/AIDS and hypertension in Africa, under U.S. Presidents Emergency Plan for Aids Relief (PEPFAR), United States partnered with AstraZeneca Plc in donating US$10 million to HIV/AIDS funding. In November 2016, ViiV Healthcare (Pfizer and GlaxoSmithKline’s joint venture) received U.S. FDA approval to market selzentry for the treatment of CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents.

 

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX

QUICKLINKS
RESEARCH AREAS
PRESS RELEASE
CONTACT US
+1-866-598-1553
EMAIL
sales@precisionbusinessinsights.com
FOLLOW US
QUICK LINKS+
RESEARCH AREAS+
PRESS RELEASE+
CONTACT US+
+1-866-598-1553
sales@precisionbusinessinsights.com
FOLLOW US AT+